Middle East & Africa Cell & Gene Therapy Bioanalytical Testing Services Market Size & Outlook
The cell & gene therapy bioanalytical testing services market in Middle East & Africa is expected to reach a projected revenue of US$ 22.3 million by 2030. A compound annual growth rate of 3.8% is expected of Middle East & Africa cell & gene therapy bioanalytical testing services market from 2024 to 2030.
HC Outsourcing
Clinical & Non-Clinical Outsourcing Services
Cell & Gene Therapy Bioanalytical Testing Services Market Outlook
MEA cell & gene therapy bioanalytical testing services market highlights
The MEA cell & gene therapy bioanalytical testing services market generated a revenue of USD 17.2 million in 2023.
The market is expected to grow at a CAGR of 3.8% from 2024 to 2030.
In terms of segment, bioavailability & bioequivalence studies was the largest revenue generating test type in 2023.
Bioavailability & Bioequivalence Studies is the most lucrative test type segment registering the fastest growth during the forecast period.
Country-wise, South Africa is expected to register the highest CAGR from 2024 to 2030.
MEA data book summary
Market revenue in 2023
USD 17.2 million
Market revenue in 2030
USD 22.3 million
Growth rate
3.8% (CAGR from 2023 to 2030)
Largest segment
Bioavailability & bioequivalence studies
Fastest growing segment
Bioavailability & Bioequivalence Studies
Historical data covered
2018 - 2022
Base year for estimation
2023
Forecast period covered
2024 - 2030
Quantitative units
Revenue in USD million
Market segmentation
Bioavailability & Bioequivalence Studies, Pharmacokinetics, Pharmacodynamics, Other test type
Key market players worldwide
IQVIA Holdings Inc, Labcorp Holdings Inc, Thermo Fisher Scientific Inc, Pharmaron Beijing Co Ltd Ordinary Shares - Class H, Charles River Laboratories International Inc, Syneos Health, Intertek Group PLC
Other key industry trends
In terms of revenue, MEA region accounted for 3.4% of the global cell & gene therapy bioanalytical testing services market in 2023.
Globally, North America is projected to lead the regional market in terms of revenue in 2030.
Asia Pacific is the fastest growing regional market and is projected to reach USD 277.6 million by 2030.
Middle Eastern countries with booming economies include Saudi Arabia, Kuwait, South Africa, and the UAE. The MEA's market for cell & gene therapy bioanalytical testing services is anticipated to expand gradually over the next several years.
The growing need for medications and the rising prevalence of diseases are among the factors responsible for market growth. Collaboration between international pharmaceutical companies, local biotech firms, academic institutions, and government agencies is essential for advancing cell and gene therapy in the MEA region.
These partnerships can help leverage resources, expertise, and funding to accelerate research, development, and access to innovative therapies. Furthermore, a lack of competition among pharmaceutical companies in the region's developing countries has resulted in an increasing number of pharmaceutical startups, which is expanding the regional market.
Middle East & Africa Cell & Gene Therapy Bioanalytical Testing Services Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cell & Gene Therapy Bioanalytical Testing Services Market Outlook will help companies and investors design strategic landscapes.
Bioavailability & Bioequivalence Studies was the largest segment with a revenue share of 35.47% in 2023.
Horizon Databook has segmented the Middle East & Africa cell & gene therapy bioanalytical testing services market based on bioavailability & bioequivalence studies, pharmacokinetics, pharmacodynamics, other test type covering the revenue growth of each sub-segment from 2018 to 2030.
Middle Eastern countries with booming economies include Saudi Arabia, Kuwait, South Africa, and the UAE. The MEA's market for cell & gene therapy bioanalytical testing services is anticipated to expand gradually over the next several years.
The growing need for medications and the rising prevalence of diseases are among the factors responsible for market growth. Collaboration between international pharmaceutical companies, local biotech firms, academic institutions, and government agencies is essential for advancing cell and gene therapy in the MEA region.
These partnerships can help leverage resources, expertise, and funding to accelerate research, development, and access to innovative therapies. Furthermore, a lack of competition among pharmaceutical companies in the region's developing countries has resulted in an increasing number of pharmaceutical startups, which is expanding the regional market.
Middle East & Africa Cell & Gene Therapy Bioanalytical Testing Services Market Indication Outlook (Revenue, USD million , 2018-2030)
Infectious Diseases
Rare Diseases
Oncology
Others
Neurological disorders
Middle East & Africa Cell & Gene Therapy Bioanalytical Testing Services Market Test Type Outlook (Revenue, USD million , 2018-2030)
Other test type
Pharmacodynamics
Bioavailability & Bioequivalence Studies
Pharmacokinetics
Middle East & Africa Cell & Gene Therapy Bioanalytical Testing Services Market Product Outlook (Revenue, USD million , 2018-2030)
Cell Therapy
Gene-Modified Cell Therapy
Gene Therapy
Middle East & Africa Cell & Gene Therapy Bioanalytical Testing Services Market Stage of Development Outlook (Revenue, USD million , 2018-2030)
Clinical
Non-Clinical
Reasons to subscribe to Cell & Gene Therapy Bioanalytical Testing Services Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cell & Gene Therapy Bioanalytical Testing Services Market Outlook databook
Our clientele includes a mix of Cell & Gene Therapy Bioanalytical Testing Services Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa Cell & Gene Therapy Bioanalytical Testing Services Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
MEA cell & gene therapy bioanalytical testing services market statistics, by indication, 2018-2030 (US$M)